Methenamine hippurate
Hiprex, Methenamine Hippurate, Urex (methenamine hippurate) is a small molecule pharmaceutical. Methenamine hippurate was first approved as Urex on 1982-01-01. It is used to treat bacteriuria, cystitis, escherichia coli infections, and staphylococcal infections in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Hiprex, Methenamine hippurate, Urex (discontinued: Methenamine hippurate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Methenamine hippurate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| UREX | Alvogen | N-016151 RX | 1982-01-01 | 1 products |
| HIPREX | Validus Pharmaceuticals | N-017681 RX | 1982-01-01 | 1 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hiprex | New Drug Application | 2022-02-02 |
| methenamine hippurate | ANDA | 2024-10-24 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 2 | — | 5 | 3 | 10 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | 2 | 3 | 6 |
| Recurrence | D012008 | — | — | — | — | — | 2 | 1 | 3 |
| Communicable diseases | D003141 | — | — | — | — | — | 1 | 2 | 3 |
| Cystitis | D003556 | EFO_1000025 | N30 | — | — | 1 | 1 | — | 2 |
| Reinfection | D000084063 | — | — | — | — | — | 1 | — | 1 |
| Female urogenital diseases | D052776 | — | — | — | — | — | 1 | — | 1 |
| Urogenital diseases | D000091642 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysuria | D053159 | EFO_0003901 | R30 | — | — | 1 | — | — | 1 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | 1 | — | — | 1 |
| Pelvic pain | D017699 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary retention | D016055 | HP_0000016 | R33 | — | 1 | — | — | — | 1 |
| Pelvic organ prolapse | D056887 | EFO_0004710 | — | — | 1 | — | — | — | 1 |
| Prolapse | D011391 | — | — | — | 1 | — | — | — | 1 |
| Spinal dysraphism | D016135 | EFO_1001210 | Q05 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Bacteriuria | D001437 | — | R82.71 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Catheter-related infections | D055499 | — | — | — | — | — | — | 1 | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | — | — | — | — | 1 | 1 |
| Lupus nephritis | D008181 | EFO_0005761 | — | — | — | — | — | 1 | 1 |
| Nephritis | D009393 | — | N05 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Methenamine hippurate |
| INN | — |
| Description | Hexamethylenetetramine is a polycyclic cage that is adamantane in which the carbon atoms at positions 1, 3, 5 and 7 are replaced by nitrogen atoms. It has a role as an antibacterial drug. It is a polycyclic cage, a polyazaalkane and a tetramine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C1N2CN3CN1CN(C2)C3.O=C(O)CNC(=O)c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 100-97-0 |
| RxCUI | 6832 |
| ChEMBL ID | CHEMBL1201104 |
| ChEBI ID | — |
| PubChem CID | 4101 |
| DrugBank | DB06799 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 234 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
387 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use